Study of WAL0921 for glomerular kidney diseases
Part of Hormones & metabolism, Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new drug called WAL0921 for people with certain types of kidney disease. The goal is to see if it can help protect kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have one of these kidney conditions: diabetic kidney disease, a type of kidney scarring (FSGS), hard-to-treat minimal change disease, IgA nephropathy, or membranous nephropathy.
- Your kidney function (eGFR) must be 30 or higher – ask your doctor for this number.
- You cannot be pregnant or planning pregnancy.
- You cannot have had an organ transplant.
- You cannot have a history of alcohol or drug abuse.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug (QLS7305) for certain kidney diseases that cause protein in the urine and can lead to kidney damage. The goal is to see if the drug helps reduce protein loss and protect kidney function.
This trial tests a new drug called YK012 for people with primary membranous nephropathy, a kidney disease where protein leaks into the urine. The goal is to see if this treatment can reduce protein loss and protect kidney function.
This Phase 1 trial tests how safe and tolerable an experimental medicine (HS-10390) is in healthy adults, and how the body processes it. It is not for people with an illness, but for healthy volunteers to help researchers understand the drug before future studies.
This trial tests a new medication for IgA nephropathy, a kidney disease that causes inflammation and protein loss in urine. It aims to see if the drug can safely slow down kidney damage and protect kidney function.
This phase 3 trial tests an experimental drug (HRS-5965) for people with IgA nephropathy (a kidney disease). It aims to find out if the drug can help reduce protein in the urine and protect kidney function. To join, you must have had a kidney biopsy showing IgA nephropathy within the past 8 years and have significant protein in your urine despite taking standard treatments.
This study tests a new drug called EVER001 to see if it can reduce protein loss in urine and improve kidney function in patients with specific kidney diseases (FSGS, MCD, or IgAN). These are autoimmune kidney conditions that cause the kidneys to leak protein into the urine.
Hear when a new Diabetic Nephropathies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.